Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
134
resultados
Última actualización
17/01/2026 [06:57:00]
Resumen de: WO2026014044A1
This blood glucose level measurement device comprises: a blood glucose level estimation unit that outputs light to a living body, detects light transmitted through the living body, calculates, on the basis of the result of the detection, a temporal phase difference between an oxygenated hemoglobin waveform relating to the oxygenated hemoglobin concentration of the blood in the living body and a deoxygenated hemoglobin waveform relating to the deoxygenated hemoglobin concentration of the blood in the living body, and calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; and a body movement detection unit that detects a parameter relating to body movement of the living body. In cases where the parameter detected by the body movement detection unit or the variation in the parameter is equal to or below a threshold value, the blood glucose level estimation unit stores the calculated blood glucose level in a storage unit.
Resumen de: AU2025203869A1
One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off. One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off. ay a y m o d u l e t u r n - o f f Start Display communication status S1201 Detect turn-off of communication module S1203 Delay display of communication module turn-off for one period of time S1205 If communication module turn-off persists for one period of time, S1207 modify display of communication status Display communication module turn-off S1209 End ay a y
Resumen de: WO2026014036A1
This blood glucose level measurement device comprises: an acquisition unit that outputs light to a living body and detects the light transmitted through the living body, thereby acquiring waveform calculation data for calculating an oxygenated hemoglobin waveform and a deoxygenated hemoglobin waveform; a phase difference calculation unit that calculates a temporal phase difference between the oxygenated hemoglobin waveform and the deoxygenated hemoglobin waveform; and a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the temporal phase difference. The acquisition unit is configured to be capable of executing first sampling for acquiring the waveform calculation data at a first sampling rate and second sampling for acquiring the waveform calculation data at a second sampling rate higher than the first sampling rate.
Resumen de: AU2025275314A1
Abstract The present disclosure provides systems and devices for combining analyte monitoring with fluid delivery, including devices that are adapted for use with combined sensors and cannulas having sensors and cannulas on a single component. These systems and devices may be used in various applications with simultaneous in vivo monitoring of analyte concentrations and delivery of medications. The systems and devices use a combined sensor and cannula attached to a body that provides electrical coupling of the sensor to a signal processing device and fluidic coupling of the cannula to a medication delivery source, in order to combine subcutaneous liquid medication delivery and amperometric analyte sensing without a need for multiple skin piercing elements.
Resumen de: US20260013801A1
Methods for predicting glucose values which involve determining a predicction time window using historical data indicative of glucose level influencing events of a person having diabetes and at least one predicted glucose level influencing event. Further disclosed are data processing systems for predicting glucose values, medical servers, user devices, and computer programs.
Resumen de: US20260013793A1
A multi-modal sensor system for monitoring a user includes a smart sock and smart insole configured to be worn on a foot of the use. The sock and insole each have a multi-modal sensor array integrated within their respective structures. For example, the sensor array may include a temperature sensor, a pressure sensor, a moisture sensor, and an optical sensor to measure multiple physiological parameters on the foot of the user. Processing electronics provide for early detection of inflammation, pressure ulceration risk, and circulation changes through coordinated wireless communication between the sock and insole for comprehensive diabetic foot health monitoring during continuous daily wear applications.
Resumen de: US20260014318A1
A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, and predicting a future blood glucose level of the person at a first time after the time window using the physiological model and the meal-specific values of the parameters of the physiological model. In one example, an alert or a notification can be sent to a user or an electronic device based on the predicted future blood glucose level of the person.
Resumen de: WO2026014636A1
Disclosed is a blood glucose management system using non-invasive blood glucose measurement. A blood glucose management system using non-invasive blood glucose measurement according to an embodiment of the present invention comprises: a non-invasive blood glucose diagnosis device which detects an electrical signal by means of contact with a finger of a user and calculates a blood glucose value by applying a preset blood glucose calculation process to the detected electrical signal; and a user terminal device which receives the calculated blood glucose value from the non-invasive blood glucose diagnosis device and generates customized blood glucose information for the user on the basis of the blood glucose value. The customized blood glucose information includes blood glucose management information, diet therapy information, and exercise therapy information corresponding to a preset management period.
Resumen de: WO2026014486A1
The present disclosure pertains to a battery and a stent comprising an electronic device. The present disclosure also pertains to a stent capable of generating a current in response to glucose. The present disclosure can provide a stent which has a hydrogel and a negative electrode, and in which the hydrogel is bonded to the surface of the stent and carries a sugar-oxidizing enzyme, the hydrogel and the negative electrode are linked together so as to be capable of receiving electrons generated by the enzyme in the hydrogel, and electrons are supplied from the negative electrode when glucose makes contact with the sugar-oxidizing enzyme.
Resumen de: WO2026015078A1
The current invention relates to compounds suitable for detecting the presence of N-Acetyl-β- D-glucosaminidase (NAG). The current invention further relates to methods of detecting the NAG in a sample obtained from a subject suspected of having increased levels of NAG comprising a step of providing a formulation comprising the compounds.
Resumen de: US20260013759A1
A diagnostic Electrochemical Impedance Spectroscopy (EIS) procedure is applied to measure values of impedance-related parameters for one or more sensing electrodes. The parameters may include real impedance, imaginary impedance, impedance magnitude, and/or phase angle. The measured values of the impedance-related parameters are then used in performing sensor diagnostics, calculating a highly-reliable fused sensor glucose value based on signals from a plurality of redundant sensing electrodes, calibrating sensors, detecting interferents within close proximity of one or more sensing electrodes, and testing surface area characteristics of electroplated electrodes. Advantageously, impedance-related parameters can be defined that are substantially glucose-independent over specific ranges of frequencies. An Application Specific Integrated Circuit (ASIC) enables implementation of the EIS-based diagnostics, fusion algorithms, and other processes based on measurement of EIS-based parameters.
Resumen de: US20260013800A1
A computer-implemented method and system for predicting and displaying glucose values, including receiving CGM data, determining, based on the data, a plurality of first predicted glucose values (33) for a first prediction time window (30), determining, based on the data, that a hypoglycemia event is predicted to occur during a second prediction time window (31) which has a contemporaneous beginning with the first prediction time window (30) but is shorter than the first window (30), and determining a plurality of second predicted glucose values (34) for the second prediction time window (31) and displaying the plurality of second predicted glucose values (34) for the second prediction time window (31) while not displaying predicted glucose values subsequent to the second prediction time window (31).
Resumen de: AU2024306140A1
Improved alarms for analyte monitoring systems are provided. For example, disclosed herein are various embodiments of methods, systems, and interfaces for long hyperglycemic alerts or pre-alerts. In addition, various embodiments of methods, systems, and interfaces for modified high glucose alerts, which predict if the high glucose episode is associated with a recently administered medication dose are described. Also, systems that include both high glucose alerts and long hyperglycemic alert options are described, in addition to enabling and disabling or suppressing certain alerts under various conditions.
Resumen de: WO2026014041A1
This blood glucose level measurement device comprises: a light output unit; a light detection unit that detects light output by the light output unit and transmitted through a living body; a temporal phase difference calculation unit that calculates the temporal phase difference between an oxygenated hemoglobin waveform and a deoxygenated hemoglobin waveform on the basis of the detection result from the light detection unit; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the temporal phase difference calculated by the temporal phase difference calculation unit; and a blood glucose level calibration unit that calibrates the blood glucose level calculated by the blood glucose level calculation unit. The blood glucose level calibration unit carries out the calibration such that the blood glucose level calculated by the blood glucose level calculation unit during sleep of the living body or during a prescribed period or time after waking up from the sleep corresponds to a preset reference blood glucose level.
Resumen de: US20260018302A1
Present disclosure describes techniques for predicting diabetes risk in patients. The techniques include the step of monitoring a plurality of patient-specific characteristics comprising, at least one physiological parameter, one behavioral indicator, and one visual representation of the patient. The method further comprises extracting, using a first artificial intelligence (AI) model, a stress level of the patient based at least on behavioral indicators, historical lifestyle data, and sensor-derived physiological parameters. The method then include extracting, using a second AI model, a body mass index (BMI) or fat distribution patterns based at least on silhouette images and weight of the patient. The method finally includes predicting, using a third AI model, a blood sugar level or diabetes risk score of the patient based on outputs from the first and second AI models and the monitored characteristics.
Resumen de: US20260018305A1
Detection of anomalous computing environment behavior using glucose is described. An anomaly detection system receives glucose measurements and event records during a first time period. Missing events that are missing from the event records during the first time period are identified by processing the glucose measurements using an event engine simulator. An anomaly detection model is generated based on the missing events during the first time period. Subsequently, the anomaly detection system receives additional glucose measurements and additional event records during a second time period. Missing events that are missing from the additional event records during the second time period are identified by processing the additional glucose measurements using the event engine simulator. Anomalous behavior is detected if the identified missing events that are missing from the event records during the second time period are outside a predicted range of missing events of the anomaly detection model.
Resumen de: EP4678094A2
The present disclosure relates to a continuous blood sugar measuring sensor member, wherein: since an electrode layer formed on one surface of a substrate is connected to a sensor contact point part on the other surface of the substrate through a via hole and thus two electrode layers may be formed on different opposite surfaces without having to be formed on the same surface of the substrate, the width of the substrate may be further reduced and an overall minimized and simplified structure may be ensured; since an electrode connection layer formed at the via hole is not formed in a shape of filling the via hole but is formed only on the inner circumferential surface, a filling defect occurring in a process of filling the via hole and a fault in electrical connection according thereto may be prevented and thus a more stable structure may be ensured; and since a plurality of via holes are formed, despite damage to or the occurrence of a defect in an electrode connection layer formed at one of the via holes, electrical connection is maintained by electrode connection layers formed at the remaining via holes, and thus more stable performance may be maintained.
Resumen de: EP4679441A1
Exemplary embodiments relate to automated medicament delivery (AMD) devices. Exemplary methods and apparatuses allow the AMD to account for the eventual impact of remaining medicament-on-board (MOB) on reduction in glucose concentrations, and do not incorporate the impact of meals on increases in glucose concentrations. This allows the AMD system to estimate the user's final glucose concentration if the impact of both carbohydrate ingestion and existing MOB are fully realized. Consequently, an AMD system can personalize its behaviors to a particular user more rapidly than if the system were to rely simply on previous medicament delivery and glucose histories. This is especially useful when a user begins using an AMD system with an inaccurate or poorly estimated initial value for total daily medicament (TDM) delivery.
Resumen de: GB2700315A
A non-invasive in vivo measurement by Raman spectroscopy of an analyte (e.g. glucose) present in the skin of a subject (e.g. in the interstitial fluid). A controllable vertical-cavity surface-emitting laser (VCSEL) source 32, spatially separated from a detector 30, irradiates the skin 33 of the subject. The VSCELs selectively change the wavelength of light in using SWEPT methodologies. A bandpass filter receives Raman scattered radiation transmitted from the sample and a processor generates a Raman spectrum from the received Raman scattered radiation. The VCSELs may be distributed around the detector. The light sources 151 may be included in a generally planar probe (e.g. provided on a PCB) integrated with a spectrometer for miniaturisation. The probe may include a slit plate 146 having a slit 148 around which the light sources are arranged. The arrangement may provide spatially offset Raman spectroscopy (SORS). Figs 3&19A
Resumen de: EP4679440A1
A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, and predicting a future blood glucose level of the person at a first time after the time window using the physiological model and the meal-specific values of the parameters of the physiological model. In one example, an alert or a notification can be sent to a user or an electronic device based on the predicted future blood glucose level of the person.
Resumen de: EP4679439A1
A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, estimating an amount of residual glucose or residual carbohydrate of the meal that would not be counteracted by insulin already delivered to the person using the physiological model and the meal-specific values of the parameters of the physiological model, and determining a dose of a correction bolus to be delivered to the person based on the amount of residual glucose or residual carbohydrate of the meal.
Resumen de: WO2026008382A1
In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and/or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.
Resumen de: WO2026008380A1
In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time. The present invention further contemplates the extraction of one or more features of the blood glucose signal received from the one or more sensors. Using this information, a relative non-digestion- related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion- related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.
Resumen de: WO2026008436A1
In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time and a biomarker signal from one or more sensors over an overlapping period of time. The present invention further contemplates the extraction of one or more features of the biomarker signal received from the one or more sensors. Using this information, a relative non-digestion-related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.
Nº publicación: WO2026008858A1 08/01/2026
Solicitante:
THE UNIV COURT OF THE UNIV OF GLASGOW [GB]
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW
Resumen de: WO2026008858A1
A blood glucose level sensing device for non-invasive blood glucose level measurement of a subject is disclosed. The device comprises: a digit-depth unit configured to measure or receive a depth of a digit of the subject; a measurement light generation element configured to direct measurement light through the digit; and a light-transmission measurement unit configured to measure a transmission index representing the proportion of the measurement light transmitted through the digit. The device also has a digit characteristic parameter unit configured to receive one or more digit characteristic parameters indicative of: a skin tone of the digit; a nail texture of the digit; a nail thickness of the digit; a nail length of the digit; and a nail polish status of the digit. The device is configured to determine a blood glucose level measurement based on the transmission index, the depth of the digit and at least one of the digit characteristic parameters. Also disclosed is a method of non-invasively determining a blood glucose level of a subject via a digit of the subject.
BOPI
Sede Electrónica
